Latest Administration News

A recent expert panel convened by Novitas has strongly endorsed Pacific Edge’s urine-based Cxbladder tests for hematuria evaluation, recommending Medicare coverage based on robust clinical evidence and patient care benefits.

Praemium Limited reported a robust half-year performance with a 69.5% jump in net profit and a 9.6% rise in funds under administration, completing the OneVue platform transition and acquiring AI specialist Technotia Laboratories.

Alfabs Australia reported a 28% revenue rise to $55.6 million in H1 2026, but EBITDA fell due to a $2.8 million Dartbrook mine impact and softer engineering margins. The company is investing heavily in mining hire assets and pursuing a strategic acquisition to drive future growth.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Guzman y Gomez has reported a robust first half of FY26, delivering strong revenue and profit growth alongside significant restaurant network expansion in Australia and the US.

Mineral Resources Limited reports a dramatic turnaround with a $573 million half-year profit, driven by Onslow Iron’s ramp-up and stronger lithium markets. The company reaffirms FY26 guidance amid strategic joint ventures and balance sheet strengthening.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

Cyclopharm Limited is rapidly scaling its US presence for Technegas®, securing new contracts across federal institutions and major health networks in four key regions. The company aims for up to 300 installations by late 2026, boosting recurring revenue streams.

Transurban Group posted robust half-year results for December 2025, with revenue climbing 8.1% and profit rebounding to $343 million. The company also declared a 34-cent interim distribution, underpinned by strong cash flow and key project milestones.

InvestSMART Group Ltd reports a solid half-year performance with funds under management reaching $750 million and a growing subscriber base, while outlining plans to enhance its digital wealth platform with AI and new services.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Cleo Diagnostics has chosen Bio-Techne’s next-generation Ella™ platform to enhance its ovarian cancer blood test, aiming for faster, more precise results and a streamlined path to FDA approval.